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Abstract
Objective—To characterize population-level surgical treatment patterns for cervical carcinoma 
in situ (CIS) reported to the Michigan Cancer Surveillance Program (MCSP), and to inform data 
collection strategies.
Methods—All cases of cervical carcinoma in situ (CIS) (including cervical intraepithelial 
neoplasia grade 3 and adenocarcinoma in situ [AIS]) reported to the MCSP during 1998–2003 
were identified. First course of treatment (ablative procedure, cone biopsy, loop electrosurgical 
excisional procedure [LEEP], hysterectomy, unspecified surgical treatment, no surgical treatment, 
unknown if surgically treated) was described by histology, race, and age at diagnosis.
Results—Of 17,022 cases of cervical CIS, 82.8% were squamous CIS, 3% AIS/adenosquamous 
CIS, and 14.2% unspecified/other CIS. Over half (54.7%) of cases were diagnosed in women 
under age 30. Excisional treatments (LEEP, 32.3% and cone biopsy, 17.3%) were most common, 
though substantial proportions had no reported treatment (17.8%) or unknown treatment (21.1%). 
Less common were hysterectomy (7.2%) and ablative procedures (2.6%). LEEP was the most 
common treatment for squamous cases, while hysterectomy was the most treatment for AIS/
adenosquamous CIS cases. Across histologic types, a sizeable proportion of women diagnosed 
≤30 years of age underwent excision, either LEEP (20%–38.7%) or cone biopsy (13.7%–44%).
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Conclusion—Despite evidence suggesting it may be safer and equally effective as excision, 
ablation was rarely used for treating cervical squamous CIS. These population-based data indicate 
some notable differences in treatment by histology and age at diagnosis, with observed patterns 
appearing consistent with consensus guidelines in place at the time of study, but favoring more 
aggressive procedures. Future data collection strategies may need to validate treatment 
information, including the large proportion of no or unknown treatment.
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adenocarcinoma; cervical carcinoma in situ; cervical intraepithelial neoplasia; hysterectomy; 
squamous cell carcinoma
Introduction
Despite dramatic declines in cervical cancer in the United States concurrent with widespread 
screening, about 12,280 women are diagnosed with invasive cervical cancer each year.1 
Cervical cancer is preceded by dysplastic changes of the cervical epithelium, known as 
cervical intraepithelial neoplasia (CIN). These CIN lesions are graded based on histological 
severity from 1 to 3, the latter including carcinoma in situ (CIS), a pre-invasive 
carcinomatous change of the cervix. High-grade CIN lesions (CIN 3) and CIS, often 
synonymous, are considered the most relevant cervical cancer precursors for diagnosis and 
treatment due to their heightened invasive potential.2 Most cervical cancers (70%) are 
squamous cell carcinomas.3 While adenocarcinomas account for a smaller proportion (20%–
25%) of all cervical cancers,3,4 registry-based studies indicate their incidence may be 
increasing.5 Adenocarcinoma in situ (AIS) is the most proximate precursor of cervical 
adenocarcinoma.
The systematic collection of data on high-grade CIN lesions could serve an important role in 
monitoring the impact of preventive measures such as newer cervical cancer screening 
guidelines and prophylactic human papillomavirus (HPV) vaccine on future disease 
burden.6,7 However, cervical cancer precursors are currently not routinely reported 
throughout the United States.6 Routine collection of CIS did occur by US cancer registries 
for several decades in the 1970s, 1980s, and early 1990s. In 1996, US cancer registries 
discontinued this practice due to concerns over the burden to reporting facilities; the quality 
of data, in light of changing diagnostic terminology for cervical cancer precursors8; and loss 
of comparability in incidence data over time and across registries.9
Despite the national decision in 1996 to stop collection of high-grade cervical cancer 
precursors, the Michigan Cancer Surveillance Program (MCSP) continued collection of 
cervical CIS/AIS data, with minimal additional resources, due to the increasing use of 
electronic case reporting.8 Because the Michigan program is the only population-based data 
source for high-grade cervical cancer precursors that has been continuously collected since 
1985, it provides a unique resource for the long-term systematic monitoring of cervical 
cancer control efforts. Analysis of MCSP data found increasing rates of cervical carcinoma 
in situ (CIS) in Michigan that nearly doubled in less than 2 decades, increasing from 31.7 
per 100,000 in 1985 to 59.2 per 100,000 in 2003. Furthermore, for every invasive cervical 
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cancer diagnosis reported during the same period, there were 7 in situ cases in white women 
and 4 in situ cases in black women.9
In women with a histological diagnosis of CIN, appropriate management is a critical 
component of cervical cancer prevention. However, very few population-based data exist on 
patterns of management for cervical cancer precursors. Surgical management options for 
CIN include ablative procedures that destroy the affected tissue in vivo (eg, cryotherapy, 
laser ablation), excisional procedures that remove the affected tissue (eg, loop 
electrosurgical excisional procedure [LEEP], laser conization, cold knife conization), and 
hysterectomy.10,11
In a systematic review published in 2000, no substantive differences were found in the 
persistence or resolution of CIN among women treated with cone biopsy, cryotherapy, laser 
ablation, or LEEP.12 A Cochrane review of the evidence through July 2004, from 28 
randomized controlled trials of alternative surgical treatments for CIN, found no 
overwhelmingly superior technique for eradicating CIN.13 The authors concluded that the 
choice of treatment should therefore be based on cost, morbidity, and the value of obtaining 
biopsy specimens.
Excisional procedures are more widely used to treat CIN in the United States,14 largely due 
to its provision of a tissue specimen for assessment of histopathology and surgical 
margins,15 and perhaps because it is believed by clinicians to more effective than ablation, 
despite evidence to the contrary.16-18 In contrast to these potential benefits, there is now 
evidence from meta-analyses of observational studies indicating potential increased risks for 
adverse pregnancy outcomes (ie, premature rupture of membranes, preterm delivery, low 
birth weight infant, and even perinatal mortality) among women treated with cold knife 
conization, LEEP, or laser conization.14,19
The objectives of this study were to characterize population-level treatment patterns for 
cervical CIS by histology, age, and race in the MCSP, and to inform future data collection 
strategies.
Materials and Methods
Data Source and Case Selection
This study was approved as exempt by the Michigan Department of Community Health’s 
Institutional Review Board. We used data collected by the MCSP, a statewide population-
based registry which has been in operation since 1981, with legally mandated cancer 
reporting and statewide population coverage since 1985.9 Methods for collection of cervical 
CIS cases through the MCSP have been described in detail.9 Briefly, the MCSP covers a 
state population of approximately 10 million, consisting of 81.2% whites, 14.2% blacks, 
2.4% Asians, 0.6% American Indians/Alaska Natives, and approximately 4.2% Hispanics.20 
All in situ and invasive cancers (other than basal or squamous cell carcinoma of nongenital 
skin) have been reportable to the MCSP as defined by the Michigan Administrative Code 
under the authority of Public Act 82 of 1984.
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Cervical CIS is collected by MSCP in either of 2 diagnostic categories: carcinoma in situ, or 
grade 3 cervical intraepithelial neoplasia (CIN 3) without any qualifier. During the study 
period, a diagnosis of CIN 3 qualified with the term “severe dysplasia” was not reportable, 
an exclusion criterion intended to increase the specificity of cervical CIS cases. For our 
analysis, all cervical CIS cases reported between 1998 and 2003 were included. Cases were 
limited to ICD-O-3 topography code C53 (cervix uteri), histology codes 8010–8560, and 
behavior code 2 (in situ neoplasms).21 The majority of cases (63.6%) were ICD-O-3 
histology code 8077, corresponding to squamous intraepithelial neoplasia grade III.21 The 
remaining cases included histology codes 8070 (squamous cell carcinoma in situ, not 
otherwise specified (NOS); 19%), 8010 (carcinoma in situ, NOS; 14.2%), 8140 
(adenocarcinoma in situ, NOS; 2.8%),21 and other, less common codes.
Classification of Variables
Histology, demographic information (race and age at diagnosis), and first course of 
treatment were collected and reported according to SEER standards.22 Histologic subtypes 
were classified according to ICD-O-3 morphology codes,21 and categorized as squamous 
CIS, AIS/adenosquamous CIS, unspecified CIS, or other specified CIS. For analysis 
purposes, unspecified CIS and other specified CIS were grouped, so that the final categories 
for histologic subtype were as follows: squamous CIS, AIS/adenosquamous CIS, and 
unspecified CIS/other CIS. Race was categorized as white, black, other, or unknown. Age at 
diagnosis was categorized as <21, 21–30, 31–45, or >45 years.
Surgical procedures were classified according to SEER variable codes for first course of 
cancer-directed surgery, and categorized as ablative procedure, cone biopsy, LEEP, 
hysterectomy, unspecified surgical treatment, no surgical treatment, and unknown if 
surgically treated. Details of the surgical procedure classification, including SEER codes, 
procedure descriptions and frequencies, are shown in a supplemental table.
Ablative procedures included surgical techniques that destroy the affected tissue in vivo. The 
two most widely used excisional modalities that remove the affected tissue, LEEP and cone 
biopsy, were kept as separate categories. Hysterectomy included total, radical, modified 
radical, and extended hysterectomy. Trachelectomy, or surgical removal of the cervix, is a 
fertility-preserving surgical alternative to a radical hysterectomy. This procedure was 
reported in only a small number of cases (n=3) and was classified as hysterectomy because it 
may be viewed as having similar severity (though, unlike hysterectomy, trachelectomy does 
not preclude future childbearing). Unspecified surgical treatment included instances where it 
was assumed a surgical treatment occurred, but the procedure could not be readily classified 
with other surgical treatments on the basis of its limited description (ie, surgery, NOS [n=4]; 
local tumor excision, NOS [n=287]). The category of “no surgical treatment” was limited to 
a single SEER variable code for “none; no surgery of primary site; autopsy only.” It was 
unknown if surgically treated included the SEER variable code for “unknown if surgery 
performed; death certificate only” as well as procedures considered part of diagnostic 
workup rather than treatment (ie, dilation and curettage/endocervical curettage [n=1,685]; 
excisional biopsy, NOS [n=275]). The category of “no surgical treatment” was kept separate 
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from “unspecified surgical treatment” and “unknown if surgically treated” since some 
women may have had contraindications to surgery.
Statistical Analysis
The distribution of age at diagnosis was tested for normality using the Shapiro-Wilk test, 
and because the resultant p-value was <0.05, age at diagnosis was compared across 
histologic subtypes using the non-parametric Kruskal-Wallis test. First course of treatment 
was described overall and by histologic subtype, and was further stratified by race and age at 
diagnosis. Analyses by race were limited to white and black women, and excluded 109 
(0.6%) women with other race due to small numbers as well as 1,865 (11%) women with 
unknown race. Analyses by age at diagnosis excluded 18 (0.1%) women for whom age at 
diagnosis was missing. The exact Cochran-Armitage trend test was used to evaluate trends 
in hysterectomy by age, stratified by histologic subtype. These trend tests compared the 
distribution of women undergoing hysterectomy with all individuals who did not undergo 
that treatment across age groups. Two-sided p-values <0.05 were considered statistically 
significant. All analyses were conducted using SAS version 9.2 (SAS Institute, Inc., Cary, 
NC).23
Results
Characteristics of the Study Population
For the period 1998 through 2003, there were 17,022 cases of cervical CIS reported to the 
MSCP (Table 1). Median age at diagnosis was 29 years. Over half (54.7%) of cases were 
diagnosed under 30 years of age and 10.3% of cases were diagnosed under age 21. Most 
women were white (73.7%). The majority of cases diagnosed during this period were 
squamous CIS (82.8%). The distribution of age at diagnosis differed significantly across 
histologic subtypes (Kruskal-Wallis p-value <0.0001; data not shown); women with AIS/
adenosquamous CIS were diagnosed at later ages (median: 33 years) than women with 
squamous CIS (median: 29 years) or unspecified/other CIS (median: 30 years). Overall, 
LEEP (32.3%) and cone biopsy (17.3%), both excisional modalities, were the most 
commonly used treatments. Fewer women underwent hysterectomy (7.2%), ablative 
procedures (2.6%) or unspecified surgical treatments (1.7%). In addition, a substantial 
proportion of women had no surgical treatment (17.8%), and for approximately one fifth of 
women (21.1%), it was unknown if they were surgically treated.
First Course of Surgical Treatment Stratified by Histologic Subtype
There were some notable differences in treatment across histologic subtypes (Table 2). 
LEEP was the most common treatment for women with squamous (33.6%) and unspecified/
other CIS (29.2%). However, the most common form of treatment among women with AIS/
adenosquamous CIS was hysterectomy (29.6%), a treatment received by only 6% of those 
with squamous CIS and 9% of those with unspecified/other CIS. Fewer women with AIS/
adenosquamous CIS received no surgical treatment (9.5%), compared to 17.9% of those 
with squamous CIS and 19.3% of those with unspecified/other CIS. Ablation was the least 
common treatment across all histologic types (0.4%–2.7%).
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First Course of Surgical Treatment Stratified by Race
Treatment patterns by race and histologic subtype, limited to 15,048 (88.4%) black and 
white women, are shown in Table 3. Among women with squamous CIS, treatments were 
similar by race, with the majority of white and black women undergoing LEEP (33.6% and 
37.4%, respectively) and cone biopsy (17.8% and 17.3%, respectively). Treatments for 
unspecified/other CIS were also similar by race, with the majority of white and black 
women also undergoing LEEP (30.2% and 28%, respectively) and cone biopsy (19% and 
20.5%, respectively). Some racial differences in treatment types were observed among 
women with AIS/adenosquamous CIS. White women had a higher proportion of 
hysterectomies (31.3%) than black women (34.8%), while black women had a higher 
proportion of cone biopsies (34.8%) than white women (23.3%). Among women with AIS/
adenosquamous CIS, a larger proportion of black women (21.7%) underwent LEEP 
compared with white women (11.7%). Of note, because there were only 23 black women 
with AIS/adenosquamous CIS in this study population, these percentages and comparisons 
should be interpreted with caution.
First Course of Surgical Treatment Stratified by Age at Diagnosis
Treatment patterns by age at diagnosis and histologic subtype, among women for whom age 
at diagnosis was known (n=17,044; 99.9%), are shown in Table 4. For all histologic 
subtypes, the proportion of women undergoing hysterectomy increased significantly with 
increasing age at diagnosis (Cochran-Armitage trend test p-value <0.05 for each histologic 
subtype). Ablative procedures were performed in small proportions of women (<3.3%) 
regardless of age at diagnosis, and were used the least among those with AIS/
adenosquamous CIS. Treatment patterns by age at diagnosis were similar for those with 
squamous CIS and unspecified/other CIS, with the majority of women with these histologic 
subtypes undergoing LEEP. However, treatment patterns were more variable among women 
with AIS/adenosquamous CIS. Among women diagnosed with this histologic subtype at <21 
and 21–30 years of age, cone biopsy was the most common surgical treatment (44% and 
35%, respectively). Among women diagnosed with this histologic subtype at later ages, 
hysterectomy was the predominant form of surgical treatment (42.2% for those diagnosed at 
age 31–45 years and 44.6% for those diagnosed at age >45 years), with substantially fewer 
women diagnosed in these age groups undergoing cone biopsy or LEEP.
Notably, across histologic subtypes, a sizeable proportion of women diagnosed ≤30 years of 
age underwent an excisional procedure, either a LEEP (20%–38.7%) or cone biopsy 
(13.7%–44%). In the subgroup of 1,749 (10.3%) women diagnosed at the youngest ages 
(<21 years), approximately one fourth (23.2%) received no surgical treatment. Excisional 
procedures were common among women diagnosed <21 years of age, for squamous CIS 
(36.1% LEEP, 13.7% cone biopsy), AIS/adenosquamous CIS (20% LEEP, 44% cone 
biopsy), and unspecified/other CIS (38.7% LEEP, 17% cone biopsy).
Discussion
In this population-based study of 17,022 women diagnosed with cervical CIS in Michigan 
during 1998–2003, excisional procedures (LEEP and cone biopsy) were the most commonly 
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used treatments. Cervical ablation was rarely performed, with less than 3.3% of women 
across all histological subtypes treated with these procedures. Consensus guidelines in place 
during the time frame of our study recommended both excision or ablation of the 
transformation zone as acceptable treatment options for women with biopsy-confirmed 
CIN2,3 and a satisfactory colposcopy.24 In women with recurrent CIN, 2,3 excisional 
treatment modalities were recommended.24 We also found that hysterectomies increased 
significantly with age, and were most commonly performed for AIS/adenosquamous CIS, in 
line with the existing recommendations against hysterectomy as primary therapy for CIN2,3 
but the recommended treatment for women with AIS who have completed childbearing.24 
We observed some potential differences in treatment for AIS/adenosquamous CIS by race, 
which may be due in part to confounding by differences in desires for future childbearing 
and/or preferences for definitive risk-eliminating surgery compared to continued 
surveillance.
There are few other population-based registry studies with which to compare the treatment 
patterns observed in our study. A small study conducted by the Romagna Cancer Registry in 
northern Italy found that, among 264 women with biopsy-confirmed CIN 3 reported to the 
registry during 1986–1993, the first course of treatment involved conization (59%), 
hysterectomy (35%), and local destructive therapy (6%).25 The authors attributed the limited 
role of conservative therapy and high prevalence of hysterectomy to a lack of ensuring 
follow-up with repeat smears and/or colposcopy.25 We observed similar proportions of 
women undergoing LEEP or conization (49.6%), but fewer women undergoing 
hysterectomy (7.2%) and ablative therapy (2.6%). The lower percentage of hysterectomies 
and ablative therapy could reflect misclassification or the preferred and popular choice of 
treatment during the study period.
A study linking the British Columbia Cancer Agency cytology database with cancer registry 
and vital statistics data found women with CIN 3 most often underwent cone biopsy18; 
however, as the purpose of their study was to examine rates of CIN2,3 and invasive cervical 
cancer following treatment, their exclusion criteria precludes direct comparison with our 
findings. Perhaps the most methodologically comparable study is an analysis published in 
1990 of the Surveillance, Epidemiology, and End Results (SEER) Program’s New Mexico 
Tumor Registry.26 Overall, of the 4,585 women diagnosed with cervical CIS during 1969–
1985, 31.1% underwent conservative treatment (conization, laser treatment, cryosurgery or 
trachelectomy), while 65.5% underwent hysterectomy.26 By the end of the 17-year period, 
the proportion of women undergoing hysterectomy had declined to 45.8% while the 
proportion of women who underwent more conservative treatments had increased to 
50.3%.26 The use of conservative treatments increased in all age groups with the largest 
increase in women under age 30.26 Interestingly, these dramatic shifts in surgical practice 
occurred in the absence of any consensus guidelines for the management of women with 
CIN, but may have reflected the advent of LEEP which could be easily performed in an 
outpatient setting.
In our study, the median age at diagnosis was 29 years, coinciding with peak childbearing 
age among American women.27 The few available registry-based studies have reported later 
ages at diagnosis, both in areas with organized cervical cancer screening such as in 
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Romagna, Italy (median: 38.5 years)25 and in areas with opportunistic cervical cancer 
screening such as in Israel (mean: 38.4 years),28 which may reflect differences in risk factors 
for CIN, socioeconomic characteristics, access to cervical cancer screening, and 
management of abnormal screening test results. In our study, a small proportion (10.3%) of 
cervical CIS cases was diagnosed at ages under 21 years. However, newer guidelines for 
screening start age combined with HPV vaccine initiatives are likely to affect diagnoses 
among the youngest women. Recent cervical cancer screening guidelines issued by both the 
American Cancer Society29-31 and the US Preventive Services Task Force32 recommend 
that screening start at age 21, regardless of sexual history. Typically, CIN 3 lesions grow 
slowly over many years before invasion33 and less than half (30%-50%) of CIN 3 lesions 
will progress to cancer34; treatment of lesions which may ultimately regress could put 
women at unnecessary risk for treatment-related side effects as well as for potential adverse 
outcomes in future pregnancies. Ongoing surveillance data are needed to inform our 
understanding of the epidemiology of cervical CIS, and registry-based studies may be 
helpful in evaluating the population-level impact of evolving screening guidelines and of 
HPV vaccination on the burden of disease, particularly among young women.
During the time frame of our study, LEEP and cone biopsy were commonly performed in 
young women with cervical squamous CIS, despite the evidence that had accumulated 
during that period for adverse obstetric effects associated with excisional treatments. Across 
histologic subtypes, a sizeable proportion of women diagnosed ≤30 years of age underwent 
either LEEP (20%–39%) or cone biopsy (14%–44%). Even in the youngest subgroup of 
women (diagnosed under age 21), excisional procedures were common. It is conceivable 
that these young women may have undergone repeat excisional procedures over their 
reproductive life span, potentially further increasing their risk of adverse outcomes in future 
pregnancies. A meta-analysis showing consistent evidence linking excisional treatments for 
CIN and adverse outcomes in future pregnancies, with risks of preterm delivery, low birth 
weight, and preterm premature rupture of membranes increased approximately twofold, was 
published after the time frame of our study (2006).19 Risks of adverse pregnancy outcomes 
were not shown for women undergoing ablative treatment.19 In the United States, 
practitioners may choose more aggressive management options even for the youngest 
women due to concerns about access to care and compliance with follow-up.
While the MCSP represents some of the best available population-level data for cervical 
CIS, several limitations must be considered. The current study likely underestimates the true 
burden of cervical CIS because CIN 3 qualified with “severe dysplasia” was not reportable 
in Michigan during the study period. As the MCSP began collecting “severe dysplasia” in 
2009, additional studies using more recent data could be useful for evaluating the sensitivity 
and specificity of the reporting definition for cervical CIS and the potential need for 
modifying or standardizing the definition. We were not able to evaluate the observed racial 
differences in surgical treatment for AIS/adenosquamous CIS for potential confounding (eg, 
by age at diagnosis) due to the small number of black women with this histological subtype 
(n=23) in our study population. As management guidelines in place at the time of study 
recommended cryotherapy, laser ablation, and LEEP as acceptable treatment modalities 
even for biopsy-confirmed CIN 1,24 reasons for the high proportion of women (17.8%) with 
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CIS that had no surgical treatment or unknown treatment (21.1%) warrant further 
investigation.
There is potential misclassification of some diagnostic procedures as treatment in the 
registry. For example, in this study, dilation and curettage or endocervical curettage was 
recorded in the registry as the first course of treatment for 1,685 (9.9%) women; for the 
purposes of our analyses, these women were included in the “unknown if surgically treated” 
category, as these procedures are generally considered part of the diagnostic workup rather 
than treatment. Data collection and coding manuals should be reviewed and, if needed, 
modified to distinguish between procedures used for diagnostic workup and those used 
therapeutically, taking into account the sequence of treatments. This process will also 
involve efforts to train the medical chart abstraction staff to improve data quality. Finally, 
choice of treatment may have been influenced by medical history (eg, remote history of 
treated CIN) that we could not capture in our analysis.
Looking forward, future changes being proposed by pathology organizations to standardize 
classification of HPV-related neoplasia of the lower genital tract35 may impact the 
interpretation of data from long-standing surveillance systems like the MCSP. Further, with 
our improving understanding of treatment-associated outcomes, the collection of relevant 
treatment details (eg, cone excised depth) could be considered. While it may be prohibitively 
burdensome to add this to existing cancer registries, newer population-based cancer 
registries and sentinel surveillance systems that begin collecting cervical cancer precursors 
to monitor the effects of HPV vaccination may be able to enhance their overall impact by 
also collecting data on relevant treatment characteristics and clinical outcomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was supported by the National Program of Cancer Registries, Centers for Disease Control and 
Prevention (grant number 5U58DP000812). Dr. Patel was supported in part through a career development award 
from the National Cancer Institute, National Institutes of Health (grant number K07CA120040). Dr. Sawaya was 
supported in part through an interprofessional agreement with the Centers for Disease Control and Prevention. The 
findings and conclusions in this report are those of the authors and do not necessarily represent the official position 
of the funding agencies.
References
1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2007 Incidence and 
Mortality Web-based Report. U.S. Department of Health and Human Services, Centers for Disease 
Control and Prevention and National Cancer Institute; Atlanta: 2010. 
2. McIndoe WA, McLean MR, Jones RW, Mullins PR. The invasive potential of carcinoma in situ of 
the cervix. Obstet Gynecol. 1984; 64(4):451–458. [PubMed: 6483293] 
3. Ries, LAG.; Melbert, D.; Krapcho, M., et al. SEER Cancer Statistics Review, 1975-2005. National 
Cancer Institute; Bethesda, MD: 2008. Based on November 2007 SEER data submission, posted to 
the SEER Web siteAvailable at: http://seer.cancer.gov/csr/1975_2005/
Patel et al. Page 9













4. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to 
squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based 
study. Gynecol Oncol. 2000; 78(2):97–105. [PubMed: 10926787] 
5. Wang SS, Sherman ME, Hildesheim A, Lacey JV Jr, Devesa S. Cervical adenocarcinoma and 
squamous cell carcinoma incidence trends among white women and black women in the United 
States for 1976-2000. Cancer. 2004; 100(5):1035–1044. [PubMed: 14983500] 
6. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of 
HPV vaccine in the United States. Vaccine. 2010; 28(30):4731–4737. [PubMed: 20188681] 
7. World Health Organization. Report of the meeting on HPV Vaccine Coverage and Impact 
Monitoring, 16-17 November 2009. Geneva, Switzerland: Available at: http://
whqlibdoc.who.int/hq/2010/WHO_IVB_10.05_eng.pdf
8. Saraiya M, Goodman MT, Datta SD, Chen VW, Wingo PA. Cancer registries and monitoring the 
impact of prophylactic human papillomavirus vaccines: the potential role. Cancer. 2008; 113(suppl 
10):3047–3057. [PubMed: 18980287] 
9. Copeland G, Datta SD, Spivak G, Garvin AD, Cote ML. Total burden and incidence of in situ and 
invasive cervical carcinoma in Michigan, 1985-2003. Cancer. 2008; 113(suppl 10):2946–2954. 
[PubMed: 18980278] 
10. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus 
guidelines for the management of women with abnormal cervical cancer screening tests. Am J 
Obstet Gynecol. 2007; 197(4):346–355. [PubMed: 17904957] 
11. Vesco, KK.; Whitlock, EP.; Eder, M., et al. Screening for Cervical Cancer: A Systematic Evidence 
Review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality; 
Rockville, MD: May. 2011 Evidence Synthesis No.86 AHRQ Publication No. 11-05156-EF-1
12. Nuovo J, Melnikow J, Willan AR, Chan BK. Treatment outcomes for squamous intraepithelial 
lesions. Int J Gynaecol Obstet. 2000; 68(1):25–33. [PubMed: 10687833] 
13. Martin-Hirsch PPL, Paraskevaidis E, Kitchener HC. Surgery for cervical intraepithelial neoplasia. 
Cochrane Database of Systematic Reviews. 2009:3.
14. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy 
outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 
2008; 337:a1284. [PubMed: 18801868] 
15. Ang C, Mukhopadhyay A, Burnley C, et al. Histological recurrence and depth of loop treatment of 
the cervix in women of reproductive age: incomplete excision versus adverse pregnancy outcome. 
BJOG. 2011; 118(6):685–692. [PubMed: 21429068] 
16. Chirenje ZM, Rusakaniko S, Akino V, Mlingo M. A randomised clinical trial of loop 
electrosurgical excision procedure (LEEP) versus cryotherapy in the treatment of cervical 
intraepithelial neoplasia. J Obstet Gynaecol. 2001; 21(6):617–621. [PubMed: 12521783] 
17. Dey P, Gibbs A, Arnold DF, Saleh N, Hirsch PJ, Woodman CB. Loop diathermy excision 
compared with cervical laser vaporisation for the treatment of intraepithelial neoplasia: a 
randomised controlled trial. BJOG. 2002; 109(4):381–385. [PubMed: 12013158] 
18. Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A. Cervical intraepithelial neoplasia 
outcomes after treatment: long-term followup from the British Columbia Cohort Study. J Natl 
Cancer Inst. 2009; 101(10):721–728. [PubMed: 19436026] 
19. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric 
outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: 
systematic review and meta-analysis. Lancet. 2006; 367(9509):489–498. [PubMed: 16473126] 
20. U.S. Census Bureau. [Accessed April 20, 2011] State and County QuickFacts. Available at: http://
quickfacts.census.gov/qfd/states/26000
21. Fritz, A.; Percy, C.; Jack, A., et al. International Classification of Diseases for Oncology. 3rd ed. 
World Health Organization; Geneva: 2000. 
22. Fritz, A.; Ries, L. The SEER Program Code Manual. 3rd ed. Cancer Statistics Branch, Surveillance 
Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National 
Institutes of Health; 1998. 
23. SAS (for Windows) [computer program]. Version 9.2. The SAS Institute; Cary, NC: 2008. 
Patel et al. Page 10













24. Wright TC Jr, Cox JT, Massad LS, Carlson J, Twiggs LB, Wilkinson EJ. 2001 consensus 
guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet 
Gynecol. 2003; 189(1):295–304. [PubMed: 12861176] 
25. Serafini M, Cordaro C, Montanari E, Falcini F, Bucchi L. Diagnosis and treatment of cervical 
intraepithelial neoplasia grade 3: a registry-based study in the Romagna region of Italy 
(1986-1993). Int J Epidemiol. 1999; 28(2):196–203. [PubMed: 10342679] 
26. Goodwin JS, Hunt WC, Key CR, Samet JM. Changes in surgical treatments: the example of 
hysterectomy versus conization for cervical carcinoma in situ. J Clin Epidemiol. 1990; 43(9):977–
982. [PubMed: 2213085] 
27. Livingston, G.; Cohn, D. The new demography of American motherhood. Pew Research Center; 
2010. 
28. Kogan L, Menczer J, Shejter E, Liphshitz I, Barchana M. Selected demographic characteristics of 
Israeli Jewish women with high-grade cervical intraepithelial neoplasia (CIN3): a population-
based study. Arch Gynecol Obstet. 2011; 283(2):329–333. [PubMed: 20191281] 
29. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for 
Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening 
guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis. 2012
30. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for 
Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening 
guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 
62(3):147–172. [PubMed: 22422631] 
31. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for 
Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening 
guidelines for the prevention and early detection of cervical cancer. Am J Clin Path. 2012; 137(4):
516–542. [PubMed: 22431528] 
32. Moyer VA. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation 
Statement. Ann Intern Med. Mar 14.2012 
33. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human 
papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011; 103(5):368–
383. [PubMed: 21282563] 
34. Yang HP, Zuna RE, Schiffman M, et al. Clinical and pathological heterogeneity of cervical 
intraepithelial neoplasia grade 3. PLOS ONE. 2012; 7(1):e29051. [PubMed: 22253702] 
35. College of American Pathologists. [Accessed November 17, 2011] HPV-related neoplasia of lower 




Patel et al. Page 11

























Patel et al. Page 12
Table 1
Characteristics of Cervical Carcinoma In Situ (CIS) Cases* in Michigan, 1998-2003 
(n=17,022)
Characteristic n (%)













Squamous CIS 14,096 (82.8)
AIS or adenosquamous CIS 514 (3.0)
Unspecified or other CIS 2,412 (14.2)
First course of cancer-directed surgery
Ablative procedure 446 (2.6)
Cone biopsy 2,942 (17.3)
LEEP 5,504 (32.3)
Hysterectomy 1,221 (7.2)
Unspecified surgical treatment 291 (1.7)
No surgical treatment 3,032 (17.8)
Unknown if surgically treated 3,586 (21.1)
AIS = adenocarcinoma in situ, LEEP = loop electrosurgical excisional procedure.
*
All cases reported to the Michigan Cancer Surveillance Program during 1998-2003 and limited to ICD-O-3 topography code C53 (cervix uteri), 
histology codes 8010-8560, and behavior code 2 (in situ neoplasms). The majority of cases (63.6%) were ICD-O-3 histology code 8077, 
corresponding to squamous intraepithelial neoplasia grade III.
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Table 2
First Course of Treatment for Cervical Carcinoma In Situ (CIS) Cases* by Histologic 
Subtype, Michigan, 1998-2003 (n=17,022)
Histologic subtype
OverallSquamous CIS AIS or adenosquamous CIS Unspecified or other CIS
(n=14,096; 82.8%) (n=514; 3.0%) (n=2,412; 14.2%) (n=17,022)
Treatment n (%) n (%) n (%) n (%)
Ablative procedure 380 (2.7) 2 (0.4) 64 (2.7) 446 (2.6)
Cone biopsy 2,370 (16.8) 124 (24.1) 448 (18.6) 2,942 (17.3)
LEEP 4,733 (33.6) 66 (12.8) 705 (29.2) 5,504 (32.3)
Hysterectomy 851 (6.0) 152 (29.6) 218 (9.0) 1,221 (7.2)
Unspecified surgical treatment 232 (1.7) 16 (3.1) 43 (1.8) 291 (1.7)
No surgical treatment 2,518 (17.9) 49 (9.5) 465 (19.3) 3,032 (17.8)
Unknown if surgically treated 3,012 (21.4) 105 (20.4) 469 (19.4) 3,586 (21.1)
AIS = adenocarcinoma in situ, LEEP = loop electrosurgical excisional procedure.
*
All cases reported to the Michigan Cancer Surveillance Program during 1998–2003 and limited to ICD-O-3 topography code C53 (cervix uteri), 
histology codes 8010–8560, and behavior code 2 (in situ neoplasms). The majority of cases (63.6%) were ICD-O-3 histology code 8077, 
corresponding to squamous intraepithelial neoplasia grade III.
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Table 3
First Course of Treatment for Cervical Carcinoma In Situ (CIS) Cases* by Histologic 















Ablative procedure 313 (3.0) 38 (1.9) 351 (2.8)
Cone biopsy 1862 (17.8) 342 (17.3) 2204 (17.8)
LEEP 3509 (33.6) 741 (37.4) 4250 (34.2)
Hysterectomy 714 (6.8) 109 (5.5) 823 (6.6)
Unspecified surgical
treatment 200 (1.9) 25 (1.3) 225 (1.8)
No surgical
treatment 1744 (16.7) 276 (13.9) 2020 (16.3)
Unknown if
surgically treated 2096 (20.1) 451 (22.8) 2547 (20.5)
AIS or adenosquamous CIS (n=483)
Ablative procedure 2 (0.4) 0 (0) 2 (0.4)
Cone biopsy 107 (23.3) 8 (34.8) 115 (23.8)
LEEP 54 (11.7) 5 (21.7) 59 (12.2)
Hysterectomy 144 (31.3) 5 (21.7) 149 (30.9)
Unspecified surgical
treatment 16 (3.5) 0 (0) 16 (3.3)
No surgical
treatment 41 (8.9) 0 (0) 41 (8.5)
Unknown if
surgically treated 96 (20.9) 5 (21.7) 101 (20.9)
Unspecified or other CIS (n=2,145)
Ablative procedure 49 (3.0) 8 (1.6) 57 (2.7)
Cone biopsy 312 (19.0) 103 (20.5) 415 (19.4)
LEEP 496 (30.2) 141 (28.0) 637 (29.7)
Hysterectomy 174 (10.6) 39 (7.8) 213 (9.9)
Unspecified surgical
treatment 38 (2.3) 1 (0.2) 39 (1.8)
No surgical
treatment 261 (15.9) 111 (22.1) 372 (17.3)
Unknown if
surgically treated 312 (19.0) 100 (19.9) 412 (19.2)
LEEP = loop electrosurgical excisional procedure, AIS = adenocarcinoma in situ.
*
All cases reported to the Michigan Cancer Surveillance Program during 1998-2003 and limited to ICD-O-3 topography code C53 (cervix uteri), 
histology codes 8010-8560, and behavior code 2 (in situ neoplasms). The majority of cases (63.6%) were ICD-O-3 histology code 8077, 
corresponding to squamous intraepithelial neoplasia grade III.
†
Does not include 109 (0.6%) women of other race and 1865 (1 1.0%) women with unknown race.
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Table 4
First Course of Treatment for Cervical Carcinoma In Situ (CIS) Cases* by Age at 


















Ablative procedure 47 (3.1) 207 (3.3) 110 (2.3) 16 (1.2)
Cone biopsy 209 (13.7) 1,026 (16.2) 878 (18.0) 255 (19.2)
LEEP 552 (36.1) 2,383 (37.6) 1,512 (31.0) 285 (21.4)
Hysterectomy 1 (0.1) 111 (1.8) 508 (10.4) 231 (17.4)
Unspecified surgical treatment 20 (1.3) 102 (1.6) 82 (1.7) 28 (2.1)
No surgical treatment 351 (22.9) 1,166 (18.4) 765 (15.7) 231 (17.4)
Unknown if surgically treated 350 (22.9) 1,344 (21.2) 1,031 (21.1) 283 (21.3)
AIS or adenosquamous CIS
Ablative procedure 0 (0) 1 (0.6) 1 (0.4) 0 (0)
Cone biopsy 11 (44.0) 62 (35.0) 41 (17.3) 10 (13.5)
LEEP 5 (20.0) 37 (20.9) 21 (8.9) 3 (4.1)
Hysterectomy 1 (4.0) 18 (10.2) 100 (42.2) 33 (44.6)
Unspecified surgical treatment 0 (0) 6 (3.4) 8 (3.4) 2 (2.7)
No surgical treatment 1 (4.0) 16 (9.0) 21 (8.9) 10 (13.5)
Unknown if surgically treated 7 (28.0) 37 (20.9) 45 (19.0) 16 (21.6)
Unspecified or other CIS
Ablative procedure 5 (2.6) 31 (3.0) 22 (2.5) 6 (2.0)
Cone biopsy 33 (17.0) 191 (18.4) 171 (19.7) 53 (17.2)
LEEP 75 (38.7) 339 (32.7) 241 (27.7) 50 (16.2)
Hysterectomy 0 (0) 27 (2.6) 119 (13.7) 71 (23.1)
Unspecified surgical treatment 3 (1.6) 21 (2.0) 17 (2.0) 2 (0.7)
No surgical treatment 53 (27.3) 200 (19.3) 136 (15.7) 72 (23.4)
Unknown if surgically treated 25 (12.9) 227 (21.9) 163 (18.8) 54 (17.5)
LEEP = loop electrosurgical excisional procedure, AIS = adenocarcinoma in situ.
*
All cases reported to the Michigan Cancer Surveillance Program during 1998-2003 and limited to ICD-O-3 topography code C53 (cervix uteri), 
histology codes 8010–8560, and behavior code 2 (in situ neoplasms). The majority of cases (63.6%) were ICD-O-3 histology code 8077, 
corresponding to squamous intraepithelial neoplasia grade III.
†
Does not include 18 (0.1%) women with missing age at diagnosis.
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